Second-generation ATP-competitive Hsp90 inhibitors, such as Ganetespib (GB) and Pimitespib (TAS-116), have shown promising efficacy in preclinical models and clinical trials, particularly for malignancies, such as lung cancer and gastrointestinal stromal tumors (GIST) (9, 10, 11, 12). The gene discussed is HSP90AA1; the disease is gastrointestinal stromal tumor.